Home›Entrectinib

Entrectinib

Also known as: Rozlytrek

Route: Oral

5 interactions on record

Entrectinib has 5 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Cyp3a Inducers, Drugs That Prolong Qtc Interval, Grapefruit Products. Patients taking Entrectinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 5
Moderate: 4

Moderate (4)

Entrectinib + Cyp3a Inducers— Coadministration decreases entrectinib plasma concentrations, which may reduce ROZLYTREK efficacy. Avoid coadministratio…
Entrectinib + Drugs That Prolong Qtc Interval— QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration with other products with known potential to p…
Entrectinib + Grapefruit Products— Grapefruit products contain CYP3A inhibitors that increase entrectinib concentrations. Avoid grapefruit products during …
Entrectinib + Mao Inhibitors— Coadministration increases entrectinib plasma concentrations, which could increase frequency or severity of adverse reac…

Entrectinib + Cyp3a Inducers🟡Moderate

Coadministration decreases entrectinib plasma concentrations, which may reduce ROZLYTREK efficacy. Avoid coadministration.

Entrectinib + Drugs That Prolong Qtc Interval🟡Moderate

QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration with other products with known potential to prolong QT/QTc interval.

Entrectinib + Grapefruit Products🟡Moderate

Grapefruit products contain CYP3A inhibitors that increase entrectinib concentrations. Avoid grapefruit products during treatment.

Entrectinib + Mao Inhibitors🟡Moderate

Coadministration increases entrectinib plasma concentrations, which could increase frequency or severity of adverse reactions. Dose reduction required for patients ≥2 years; avoid in patients <2 years.

Entrectinib + Itraconazoleℹ️Unknown

Entrectinib Pemigatinib Talazoparib Refer to the entrectinib, pemigatinib and talazoparib prescribing information for dosing instructions if concomitant use cannot be avoided.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.